Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Evaluate Vantage Homepage
  3. Events

Events

Thumbnail
May 13, 2022

EHA 2022 preview – some good news at last

Positive data result in positive share price movements – something of a novelty in the current market.

Thumbnail
May 11, 2022

Pressure piles up on pamrevlumab

After the latest roxadustat clanger a phase 3 interim analysis in pancreatic cancer becomes even more important for Fibrogen.

Article image
Vantage logo
May 06, 2022

Asco 2022 – Affimed suffers withdrawal symptoms

Article image
Vantage logo
April 29, 2022

Go or no go? Lilly’s valuable diabetes contender

Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.

Article image
Vantage logo
April 28, 2022

Asco 2022 – early focus settles on Adicet

Article image
Vantage logo
April 12, 2022

AACR 2022 – Novartis’s late Kras challenge to Amgen

Targeting Shp2 has disappointed, but Novartis shows that it might still make an impression in directly hitting Kras.

Article image
Vantage logo
April 11, 2022

AACR 2022 – A weekend of updates yields few winners

The dour biotech market sees little to be impressed about in updates from Bicycle, Rubius, C4 and Zentalis, though well-received data gives Affimed a boost.

Article image
Vantage logo
April 10, 2022

AACR 2022 – Biontech’s cell therapy effort bears fruit at last

But it’s still far too early to tell whether combining Car-T with an mRNA vaccine might improve response durability.

Article image
Vantage logo
April 10, 2022

AACR 2022 – Affimed shows that 2021 was no fluke

An academic-sponsored trial gives Affimed’s NK cell engaging approach a huge endorsement.

Article image
Vantage logo
April 06, 2022

Protagonist seeks an Ideal readout

A mid-stage hit with its ulcerative colitis project could see the company on course for blockbuster sales.

Vantage logo
April 05, 2022

ACC 2022 – Astra’s cholesterol lowerer surprise comes just a little late

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.